XNAS
GBIO
Market cap25mUSD
Jun 12, Last price
0.38USD
1D
-2.05%
1Q
-20.21%
IPO
-98.33%
Name
Generation Bio Co
Chart & Performance
P/E
—
P/S
1.29
EPS
—
Div Yield, %
—
Shrs. gr., 5y
7.59%
Rev. gr., 5y
177.31%
Revenues
20m
+236.92%
Net income
-132m
L+3.99%
CFO
-89m
L+67.91%
Earnings
Aug 05, 2025
Profile
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 19,892 236.92% | 5,904 | |||||
Cost of revenue | 99,085 | 224,282 | 146,312 | ||||
Unusual Expense (Income) | |||||||
NOPBT | (79,193) | (218,378) | (146,312) | ||||
NOPBT Margin | |||||||
Operating Taxes | (4,543) | ||||||
Tax Rate | |||||||
NOPAT | (79,193) | (218,378) | (141,769) | ||||
Net income | (131,668) 3.99% | (126,612) -4.15% | (132,096) 15.20% | ||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | 36,000 | 11,779 | |||||
BB yield | -33.84% | -5.16% | |||||
| Debt | |||||||
Debt current | 13,006 | 18,413 | 7,086 | ||||
Long-term debt | 174,114 | 187,668 | 156,328 | ||||
Deferred revenue | 41,942 | ||||||
Other long-term liabilities | 29,384 | ||||||
Net debt | 1,897 | (58,283) | (121,369) | ||||
| Cash flow | |||||||
Cash from operating activities | (88,563) | (52,745) | (102,448) | ||||
CAPEX | (2,401) | (7,397) | (8,801) | ||||
Cash from investing activities | 94,529 | (9,698) | (192,515) | ||||
Cash from financing activities | 250 | 35,817 | 12,989 | ||||
FCF | (19,145) | (232,606) | (132,163) | ||||
| Balance | |||||||
Cash | 185,223 | 264,364 | 279,091 | ||||
Long term investments | 5,692 | ||||||
Excess cash | 184,228 | 264,069 | 284,783 | ||||
Stockholders' equity | (702,879) | (571,096) | (444,842) | ||||
Invested Capital | 912,027 | 914,060 | 809,042 | ||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | 66,624 | 64,484 | 58,115 | ||||
Price | 1.06 -35.76% | 1.65 -58.02% | 3.93 -44.49% | ||||
Market cap | 70,622 -33.62% | 106,398 -53.41% | 228,392 -42.70% | ||||
EV | 72,519 | 48,115 | 107,023 | ||||
EBITDA | (82,115) | (213,115) | (141,182) | ||||
EV/EBITDA | |||||||
Interest | 4,543 | ||||||
Interest/NOPBT | |||||||